{"commentary":{"count":66,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":33,"youtube":21,"podcast":11,"x_video":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT02761057\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"NCT02761057","nct_id":"NCT02761057","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct02761057. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":null,"arms":[{"description":"Patients receive sunitinib malate PO QD on days 1-28. Cycles repeat every 42 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT at screening and on study, undergo bone scan as clinically indicated, and undergo collection of plasma and serum samples at screening, on study, and during follow up.","label":"Arm I (sunitinib malate)","type":"EXPERIMENTAL"},{"description":"Patients receive cabozantinib s-malate PO QD on days 1-42. Cycles repeat every 42 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT at screening and on study, undergo bone scan as clinically indicated, and undergo collection of plasma and serum samples at screening, on study, and during follow up.","label":"Arm II (cabozantinib s-malate)","type":"EXPERIMENTAL"},{"description":"Patients receive crizotinib PO BID on days 1-42. Cycles repeat every 42 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT at screening and on study, undergo bone scan as clinically indicated, and undergo collection of plasma and serum samples at screening, on study, and during follow up.","label":"Arm III (crizotinib closed to accrual 12/5/18)","type":"EXPERIMENTAL"},{"description":"Patients receive savolitinib PO QD on days 1-42. Cycles repeat every 42 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT at screening and on study, undergo bone scan as clinically indicated, and undergo collection of plasma and serum samples at screening, on study, and during follow up.","label":"Arm IV (savolitinib closed to accrual 12/5/18)","type":"EXPERIMENTAL"}],"collaborators":["Canadian Cancer Trials Group"],"completion_date":{"date":"2023-10-19","type":"ACTUAL"},"conditions":["Locally Advanced Papillary Renal Cell Carcinoma","Metastatic Papillary Renal Cell Carcinoma","Stage III Renal Cell Cancer AJCC v7","Stage IV Renal Cell Cancer AJCC v7","Type 1 Papillary Renal Cell Carcinoma","Type 2 Papillary Renal Cell Carcinoma","Unresectable Renal Cell Carcinoma"],"enrollment":{"count":152,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Biospecimen Collection","type":"PROCEDURE"},{"name":"Bone Scan","type":"PROCEDURE"},{"name":"Cabozantinib S-malate","type":"DRUG"},{"name":"Computed Tomography","type":"PROCEDURE"},{"name":"Crizotinib","type":"DRUG"},{"name":"Savolitinib","type":"DRUG"},{"name":"Sunitinib Malate","type":"DRUG"}],"last_update":"2025-01-13","lead_sponsor":"National Cancer Institute (NCI)","official_title":"A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2023-10-19","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression Free Survival (PFS)","timeFrame":"From date of registration to date of first documentation of progression or symptomatic deterioration, or death due to any cause; assessed up to 3 years"}],"references":[{"citation":"Barata P, Tangen C, Plets M, Thompson IM Jr, Narayan V, George DJ, Heng DYC, Shuch B, Stein M, Gulati S, Tretiakova M, Tripathi A, Bjarnason GA, Humphrey P, Adeniran A, Vaishampayan U, Alva A, Zhang T, Cole S, Lara PN Jr, Lerner SP, Balzer-Haas N, Pal SK. Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell Carcinoma. J Clin Oncol. 2024 Nov 20;42(33):3911-3916. doi: 10.1200/JCO.24.00767. Epub 2024 Sep 10.","pmid":"39255440","type":"DERIVED"},{"citation":"Aldin A, Besiroglu B, Adams A, Monsef I, Piechotta V, Tomlinson E, Hornbach C, Dressen N, Goldkuhle M, Maisch P, Dahm P, Heidenreich A, Skoetz N. First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2023 May 4;5(5):CD013798. doi: 10.1002/14651858.CD013798.pub2.","pmid":"37146227","type":"DERIVED"},{"citation":"Pal SK, Tangen C, Thompson IM Jr, Balzer-Haas N, George DJ, Heng DYC, Shuch B, Stein M, Tretiakova M, Humphrey P, Adeniran A, Narayan V, Bjarnason GA, Vaishampayan U, Alva A, Zhang T, Cole S, Plets M, Wright J, Lara PN Jr. A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial. Lancet. 2021 Feb 20;397(10275):695-703. doi: 10.1016/S0140-6736(21)00152-5. Epub 2021 Feb 13.","pmid":"33592176","type":"DERIVED"}],"start_date":{"date":"2016-07-25","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed","url":"https://clinicaltrials.gov/study/NCT02761057"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct02761057"}